Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of SCT520FF for neovascular age-related macular degeneration
CTR20243799Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Nov 2024
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SCT-520FF in exudative macular degeneration, sponsored by Sinocelltech Group Limited. Started Nov 2024; status: active.
02
Drugs
SCT-520FF
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20243799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243799.